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ABSTRACT:
The androgen receptor (AR) is known to play a critical role in prostate cancer (PC). 
p53 likely also plays a role given that p53 mutations are commonly found in advanced 
PC, and loss of wild-type protein function contributes to the phenotype of castration-
resistant prostate cancer (CRPC). Nevertheless, the extent of the contribution of p53 
dysfunction to PC remains unclear. Here we analyze the effects of p53 inhibition in PC 
cells and show that it has significant consequences for both the interaction between 
AR, and chromatin and the proliferative capacity of these cells. Inhibition of p53 
expression enabled LNCaP cells to proliferate independently of androgens. Moreover, 
it modified the genome-wide binding pattern of AR. ChIP-sequnce analyis (ChIP-seq) 
revealed that fewer AR-binding sites were present in the context of p53 inhibition, 
suggesting that wild-type p53 is required for stable binding of AR to certain chromatin 
regions. Further analysis revealed that a lower AR occupancy was accompanied by a 
reduction in FoxA1 binding at regulatory regions of AR-dependent genes. Our study 
also identifies a pool of genes that may be transcriptionally regulated by AR only in the 
absence of p53, and that may contribute to the CRPC phenotype. Overall, our results 
point to p53 playing an important role in regulating AR activity across the genome.
INTRODUCTION
Androgen deprivation therapy is currently the 
standard treatment for locally advanced, recurrent, or 
metastatic prostate cancer (PC). However, most patients 
with metastatic carcinomas progress to a state of disease 
insensitive to androgen ablation, called castration resistant 
prostate cancer (CRPC) [1, 2]. The systemic treatment 
options for CRPC are limited, largely because of our 
poor understanding of the molecular underpinnings of 
this disease state. The majority of CRPCs continue to 
express the androgen receptor (AR) and are dependent 
on AR signaling for malignant progression [3-5]. p53 is 
also thought to play a role in PC progression, although 
the extent of its contribution is poorly understood. 
Mutations of p53 are uncommon in primary PC, but occur 
quite frequently in advanced disease [6, 7]. In fact, a 
recent study has suggested that mutations in p53 lead to 
CRPC; Burchardt et al., (2001) [8] showed convincingly 
that a reduction in p53 expression or function in LNCaP 
confers the ability to form tumors in castrated male nude 
mice (parental LNCaP cells do not have this ability). In 
addition, AR and p53 can mutually regulate one another 
[9, 10]. Both p53 and AR are transcription factors and can 
affect the expression of a broad array of genes. It is also 
possible that an alteration in p53 affects transcriptional 
function of AR, and vice versa. 
AR is a ligand-dependent transcription factor. In 
the absence of androgen binding, it is expressed diffusely 
throughout the cytoplasm, and held in an inactive state 
through its association with chaperones such as heat 
shock proteins (HSPs). Androgen binding releases 
AR from HSPs, facilitating AR homodimerization and 
nuclear translocation. Activated AR dimers then bind to 
DNA at specific sequences termed “androgen-response 
elements” (AREs) within target-gene regulatory regions. 
Here they serve as a platform for the recruitment of 
co-activators and the basal transcriptional machinery, Oncotarget 2012; 3:  183-194 184 www.impactjournals.com/oncotarget
modulating gene expression to promote diverse biological 
outcomes. Transcription factors also have the ability to 
regulate gene expression by tethering to other response 
elements through protein-protein interaction with other 
DNA-bound factors. Thus, AR might indirectly bind to 
non-ARE sequences in the genome, through a tethering 
mechanism that involves other transcription factors such 
as AP-1 and Sp1 as was shown for estrogen receptor [11, 
12]. Thus, the control of AR target genes involves long-
range combinatorial regulation of: AR, DNA-binding 
collaborating transcription factors, and non-DNA binding 
co-regulatory factors [13-15]. 
CRPCs were recently reported to feature an altered 
expression program (with respect to parental PCs), 
accompanied by a novel AR cistrome [16], which is highly 
enriched for the FKH motif [14, 17]. FoxA1, also known 
as hepatocyte nuclear factor ΗΝF-3-alpha, is a key partner 
for ERα and AR in promoting transcriptional activity in 
breast and prostate cancer, respectively, and recognizes 
the FKH motif. FoxA1 interacts with the AR in PC cells, 
where it influences the regulation of AR target genes [18] 
by acting as a pioneer factor in binding to nucleosomal 
DNA. FoxA1 differential binding to chromatin sites 
is dependent on the distribution of histone H3 lysine 4 
(H3K4) dimethylation. Increased H3K4 dimethylation 
may thus lead to increased recruitment of FoxA1, which 
in turn would facilitate AR occupancy [16]. 
To understand the role of p53 in so called “androgen-
independent’’ cell growth of PC, we evaluated the 
effects of p53 inhibition on the genome-wide chromatin 
localization of AR in LNCaP. We found that in the absence 
of p53, the number of AR-binding peaks is significantly 
Figure 1: Effects of p53 inhibition on proliferation of LNCaP and on the specificity of chromatin binding by AR. A) 
Bar graph depicting the effects of p53 inhibition on androgen-independent proliferation in LNCaP. Error bars represent mean ±SEM, where 
n=3. Day 0 expression of p53 in LNCaP and LNsip53 cells was examined by western blot analysis, as shown above the 0-day bars. B) Bar 
graphs depicting effects of p53 inhibition on AR reporter activity in three distinct prostate cancer lines (LNCaP, C4-2B, and Rv1) stably 
transfected with an ARE-Luc construct, as assessed by luciferase assay. Error bars represent mean ±SEM, where n=3. C) EMSA assessing 
the effects of p53 inhibition on binding of AR and FoxA1 to DNA, in lysates of androgen-deprived LNCaP and LNsip53 cells treated with 
10 nM of DHT. The 32P-end labeled probe for AR (upper panel) was an ARE, and that for FoxA1 (lower panel) was TTS (FoxA1 responsive 
element). Image shown is representative of three replicate experiments. D) ChIP-PCR assessing the effects of p53 inhibition on occupancy 
of the probasin promoter (PB) by AR and FoxA1, in both LNCaP and C4-2B. Anti-AR and anti-FoxA1 antibodies were used for IP, and 
primers specific for the PB promoter were used for PCR (-242/-100). Images shown are representative of three replicate experiments.Oncotarget 2012; 3:  183-194 185 www.impactjournals.com/oncotarget
reduced, and also that some of those peaks are unique. 
RESULTS
p53 inhibition interferes with PC cell proliferation 
and with binding of the AR to DNA 
To investigate the role of p53 in the proliferation 
of PC cells, we used LNCaP that were stably transfected 
with sip53 (LNsip53) or siE6 (LNsiE6), as previously 
described [10]. It is well established that LNCaP cells 
do not proliferate if cultured in charcoal-stripped (CSS) 
medium, which lacks androgens. We plated the same 
number of LNCaP control and LNsip53 cells in CSS 
medium and, after 10 days, detected a 1.5-2.0 fold 
increase in cell number for LNsip53, but not control 
cells (Fig. 1A). p53 expression at day 0 was verified by 
western blot analysis, as shown above the 0-day column in 
Fig.1A; p53 expression was undetectable in the LNsip53 
cells. To examine the influence of p53 inhibition on AR 
activity, we used cells permanently transfected with a 
luciferase reporter under control of the probasin (PB) 
promoter. In this case, not only LNCaP (LNCaP-ARE-
Luc, LNsip53-ARE-Luc) was used, but also C4-2B-
ARE-Luc, C4-2Bsip53–ARE-Luc and 22Rv1-ARE-Luc, 
22Rv1sip53-ARE-Luc. LNCaP is the most common 
and well characterized prostate cell line and exhibit 
many of the properties of androgen dependence seen in 
clinical disease. In addition to LNCaP only few cell lines 
expressing AR protein have been described and almost all 
of them express wild type of p53. In addition to LNCaP 
we used bone metastatic LNCaP derivative C4-2B, and 
the CWR22 androgen independent derivative Rv1 cell 
line that express both full length and truncated isoform 
Figure 2: ChIP-Sequence analysis of AR binding sites in LNCaP and LNsip53. (A) Venn diagram showing overlap between 
the AR binding sites identified in LNCaP and LNsip53 by ChIP-Seq analysis.  Peaks meeting the default threshold score of 13 using the 
Partek GS peakfinding software were aligned based on matches in genomic coordinates. (B) Pie chart indicating relative enrichment of 
ChIP regions in genomic regions of potential importance, including as promoters, sequences immediately downstreams of genes, and 
introns. This analysis was carried out for peaks identified in (A), and CEAS was used for annotation. (C) Pie charts showing the percentages 
of peaks in LNCaP and LNsip53 that contain an AR or other motif (as identified using CEAS). (D)  LOGOs (graphical representation of the 
sequence conservation of nucleotides in a strand of DNA) derived by motif enrichment analysis in AR-bound regions of DNA. The most 
commonly identified (by CEAS) motifs among the predicted peaks were: the classical ARE binding site, AR-half sites, and FoxA family 
response elements. All identified LOGOS are listed in Figures S1 and S2.Oncotarget 2012; 3:  183-194 186 www.impactjournals.com/oncotarget
of AR. We also considered using MDA-PC-2b derived 
from a bone metastases and which express both AR and 
p53. However we could not obtain viable cells after 
transfection experiments. 
Cells from each of these lines were cultured in CSS 
for three days, and were then either left untreated or treated 
with 10 nM DHT for 24 hours. As shown in Fig. 1B (top 
left panel), basal levels of AR activity were significantly 
lower in LNsip53-ARE-Luc than in LNCaP-ARE-Luc 
cells. Although DHT treatment induced AR activity in 
both cell lines, luciferase activity was 5 times lower in 
the LNsip53-ARE-luc line (Fig.1B top right panel), which 
may be related to low background in these cells. The 
same trend was observed in C4-2B and 22Rv1 cells (Fig. 
1B, lower panels). We thus suggest that inhibiting p53 
expression minimizes the luciferase response in PC cells 
by changing AR-mediated transcriptional activation
Given that FoxA1 is a critical facilitator of DNA 
binding by nuclear receptors, we examined the binding of 
FoxA1 to DNA in the same cell lines. First, we carried 
out an electromobility shift assay (EMSA) to compare AR 
and FoxA1-DNA binding to oligonucleotides containing 
Figure 3: Mapping of ChIP-enriched signals to predicted genes and validation of the interaction. (A) Venn diagram 
showing overlap between the AR-regulated genes in LNCaP and LNsip53 cells. Peaks from Fig 2A were mapped to genes using CEAS. (B) 
ChIP-seq analysis of the peaks that are shared by the two datasets and that correspond to known target genes. Visualization of AR binding 
to previously reported target genes KLK3 (PSA), FKBP5, TACC2, and SLC43A1, was performed using UCSC Genome Browser images. 
(C) ChIP-PCR confirming that AR binds to the identified genes.Oncotarget 2012; 3:  183-194 187 www.impactjournals.com/oncotarget
classical AREs or TTS (FoxA1 responsive element). As 
shown in Fig. 1C, there were no significant differences in 
the in vitro DNA binding of either AR or FoxA1 between 
LNCaP and LNsip53, before or after DHT treatment. 
Likewise, FoxA1 bound to the classical response element 
in the TTS oligonucleotide probe in both sets of untreated 
cells. Pretreatment of the samples with anti-AR or anti-
FoxA1 antibody, however, affected DNA-protein mobility: 
the application of anti-AR yielded a supershifted band; 
the application of anti-FoxA1 resulted in significantly 
diminished DNA binding. These results confirm that the 
binding observed was specific. 
We next carried out ChIP analysis to investigate 
the binding of AR and FoxA1 to the PB promoter on 
our luciferase reporter. To this end, we treated LNCaP-
ARE-Luc control, LNsip53-ARE-Luc, C4-2B-ARE-Luc 
or C4-2Bsip53-ARE-Luc cells with DHT after 3 days 
of culture in CSS, and performed ChIP using AR or 
FoxA1 antibodies. We then performed PCR using primers 
specific to the PB region of this plasmid and quantitated 
the results by densitometry. As shown in Fig 1D, the 
levels of PCR products from AR-ChIP were higher in 
LNCaP than in LNsip53 (left panel); this difference was 
even greater when the cells were treated with DHT. The 
results for the FoxA1-ChIP samples were essentially the 
same. Moreover, the same patterns were found for AR- 
and FoxA1-ChIP in C4-2B and C4-2Bsip53 (Fig. 1D, 
right panel). Therefore, the lower occupancy of the PB 
Figure 4: Analysis of LNCaP-specific AR-binding peaks in ACCA and NRP1 genes. (A) ChIP-seq defined four peaks of 
LNCaP-specific binding of AR to introns within the ACCA gene, and to one intron of the NRP1 gene. Comparison to encode histone modes 
trek in the Genome Browser reveal that the AR binding peak in the NRP1 gene overlaps with the CTCF-binding peaks in a broad spectrum 
of cell lines (shown on the left). (B) ChIP-PCR confirming binding of AR and FoxA1 to ACCA and NRP1 introns in LNCaP. (C) Semi-
quantitative RT-PCR of ACCA and NRP1, revealing mRNA levels after DHT treatment. mRNA levels for ACCA (left panel) and NRP1 
(right panel) were calculated with respect to GAPDH; levels in untreated LNCaP cells were arbitrarily defined as equivalent to 1. Error bars 
represent mean ±SD, where n=3.Oncotarget 2012; 3:  183-194 188 www.impactjournals.com/oncotarget
promoter by FoxA1 and AR in LNsip53-Luc and C4-
2Bsip53-Luc cells appears to account for the reduced 
transcription observed in these contexts (luciferase assay, 
Fig. 1B), and this phenomenon appears to be common to 
multiple PC lines. The difference in the binding of both 
AR and FoxA1 to DNA in the presence (LNCaP) vs. the 
absence (LNsip53) of p53 suggests that these cells have 
epigenetic differences. 
Inhibition of p53 expression changes genome-wide 
patterns of AR binding to DNA 
To determine whether eliminating wild type p53 
affects the binding of AR to DNA throughout the genome, 
Figure 5: ChIP-seq analysis of LNsip53-specific AR-binding peaks. (A) Visualization of AR binding to introns of ASH2L 
and C11orf54, and to sequences downstream of Wig-1. (B) ChIP-PCR verifying that AR binds to DNA downstream of Wig-1. Primers 
were derived from ChIP-seq analysis. (C) Semi-quantitative RT-PCR levels of the Wig-1 mRNA. (D) Overexpression of Wig-1 inhibits 
prolifiration  48  hours  after  DHT  treatment.  Cells  were  labeled  with  [3H]-thymidine for 16 hours prior to harvesting. Incorporated 
radioactivity was measured by liquid scintillation counting. Error bars represent mean ±SEM, where n=6. Western-blotting confirming 
Wig-1 overexpression is shown above the graph. (E) Wig-1 overexpression inhibits LNsip53 growth in the absence of androgens. Cells 
were incubated in CSS for 11 days, and cell number was then counted. Error bars represent mean ±SEM, where n=3.  Oncotarget 2012; 3:  183-194 189 www.impactjournals.com/oncotarget
we performed ChIP-sequence analysis (ChIP-seq). We 
obtained 12,331,952 and 11,788,138 DNA sequence reads 
for LNCaP and LNsip53, respectively. These reads were 
mapped to the human genome (hg18) and corresponded 
to 4488 [3363 + (1125)] and 1822 [697 + (1125)] unique 
peaks, respectively (Fig. 2A). Of these, 1822 represented 
AR binding sites in LNsip53, 1125 (62%) of which 
overlapped with those identified in control LNCaP cells 
(Fig. 2A), demonstrating that some aspects of the AR 
binding profile are shared in the two cell lines, but that 
p53 inhibition also leads to AR binding at unique genomic 
positions. 
In both cell lines, the majority of peaks were located 
in either the intron of a known gene or an intergenic region 
located more than 10 kb from the nearest gene (Fig. 2B). 
Notably, fewer intronic peaks were found in LNsip53 than 
LNCaP. Also, fewer than 1% of the peaks localized to a 
proximal promoter or 5’-untranslated region of a known 
gene, consistent with previously published data for AR 
[19]. Therefore, long-range, AR-mediated regulation 
of genes from distal sites is most likely a common 
mechanism in AR-positive PCs.
We next analyzed motif enrichment in AR-bound 
regions of DNA, using the cis-regulatory element 
annotation system (CEAS) [20]. Of the 4488 AR-specific 
binding  sites  identified  in  LNCaP  cells,  2105  (47%) 
contained AREs and 618 (14%) contained response 
elements for other transcription factors but no AREs (Fig. 
2C). In LNsip53, only 265 of 1810 (15%) peaks contained 
AREs (Fig. 2C). All identified peaks are described in Table 
S1 (LNCaP) and Table S2 (LNsip53). As expected, the 
most common motifs in both cell lines were: classical ARE 
binding sites, AR-half sites and FoxA family response 
elements (Fig. 2D and Table S3). However, additional 
response elements were also found specifically in the in 
LNCaP-AR set, for example FoxO1, FoxO3, Freac-2, 
HFH4, GATA. (Table S3. All motif LOGOS for LNCaP 
and LNsip53 are listed in Figures S1 and S2, respectively). 
Analysis of AR binding peaks shared by LNCaP 
and LNsip53 cells
ChIP-seq or ChIP-on-ChIP analysis of LNCaP cells 
was previously reported [16, 21]. We have compared peaks 
for LNCaP detected in our analysis with those from Yu et 
al, 2010 and found 75% overlap. Using CAES, we mapped 
the regions identified by ChIP to the nearest genes; 2359 
and 676 genes (listed in Tables S4 and S5) were present 
near peaks for the LNCaP and LNsip53, respectively 
(Fig.3A). The percentage of peaks identified near genes 
with respect to the number of total peaks was lower in 
LNsip53 (37, 3%) vs. LNCaP (54, 6%) cells. Comparison 
of the identified genes revealed that 501 (74%) of those 
found in LNsip53 were also found in LNCaP (shared 
group); 175 (26%) genes were unique to LNsip53 cells. 
The majority of genes from the shared group had 
previously been reported as AR regulated. We found 
AR binding peaks near known AR regulated genes such 
as KLK3, KLK2, FKBP5, TACC2 and SLC43A1, all of 
which are reported to be AR-regulated. In both cell lines, 
AR-specific peaks were found in the enhancer region of 
KLK3, an upstream enhancer and an intron of FKBP5, 
and an intron of TACC2 and SLC43A1 (Fig. 3B). We 
confirmed binding at these sites by ChIP-PCR, using anti-
AR and anti-FOXA1 antibody and primers for specific 
regions (Fig. 3C). The mRNA level of FKBP5 and KLK3 
dramatically increased after 8 and 24 hours of DHT 
treatment for both cell lines (data not shown). Thus, we 
did not find differences in gene expression in overlapping 
group.
Analysis of LNCaP specific AR-binding peaks 
Of the list of LNCaP-specific genes, we examined 
Acetyl-CoA-carboxylase-α  (ACCA)  and  neuropilin-1 
(NRP1). In the case of AACA, we found 4 peaks within 
intronic regions (Fig. 4A, numbered from right to left 
starting at the beginning of the gene). Analysis of the DNA 
sequences corresponding to the peaks revealed that each 
peak contained multiple AR and FoxA1 response elements 
(Table S6). We verified all 4 peaks in LNCaP using ChIP-
PCR (with anti-AR antibody) [22]. 
The NRP1 gene had one peak specific to LNCaP 
(Fig.4B). We compared this peak to enrichment of the 
H3K4Me2, H3K4Me3, H3K9ac, and H3K27ac histone 
marks across the genome of HepG2 cells, available on 
the UCSC browser. We chose to assess the levels since 
these marks are associated with transcriptional initiation 
and opening of chromatin structure. We also compared 
Figure  6:  Schematic  depicting  model  for  LSD1 
regulation  by  p53  and AR.  When LSD1 interacts with 
oligomerized p53, H3K4 is demethylated and this leads to a 
repression of target-gene expression (left branch). When LSD1 
interacts with dimerized AR, H3K9 is demethylated and target 
genes are activated (right branch). In normal prostate cells there 
is likely a balance between the two pathways, but in the context 
of the many CRPCs with reduced p53 function, the right branch 
would be overactive.Oncotarget 2012; 3:  183-194 190 www.impactjournals.com/oncotarget
it  to  the  mark  of  the  CTCF  zinc  finger  transcription 
factor in 8 cell lines featured in the UCSC browser. 
CTCF is a sequence-specific DNA binding protein that 
functions as an insulator, blocking enhancer activity. 
Depending on the cellular context, CTCF can bind a 
histone acetyltransferase (HAT)-containing complex and 
function as a transcriptional activator, or bind a histone 
deacetylase (HDAC)-containing complex and function 
as a transcriptional repressor. We found that the AR peak 
in NRP1 in LNCaP overlapped with peaks in CTCF in 
the 8 cell lines in UCSC browser (Fig. 4A). Analysis of 
NRP1 DNA sequences from the AR-DNA binding region 
revealed three potential AR half binding sites and two 
FoxA1 binding sites. The AR half sites are shown in red 
in Table S6.
We next performed ChIP-PCR on LNCaP and 
LNsip53, with specific primers flanking these peaks. As 
shown in Fig. 4B, AR occupancy of the genomic region 
represented by the ACCA and NRP1 peaks was detected 
in both cell lines after DHT treatment, but was much 
lower in the LNsip53 cells. Occupancy of these regions 
by FoxA1 was observed predominantly in LNCaP, with 
lower levels in LNsip53. The levels of ACCA and NRP1 
mRNAs increased after 8 hours of DHT treatment in the 
LNCaP, but did not change in the LNsip53 (Fig. 4C). This 
finding indicates that AR-dependent promotion of ACCA 
and NRP1 expression is diminished in the absence of p53. 
Analysis of LNsip53 specific AR-binding peaks 
LNsip53-specific AR-binding peaks were the most 
intriguing group. However the height of AR binding 
peaks for this group was 3 times lower on average then in 
LNCaP and this group had a high number of false positive 
peaks. For example, using the USCS genome browser 
we could visualize LNsip53 specific peak in an intron of 
ASH2L (Fig. 5A, upper panel). The DNA sequence under 
this peak contains a FoxA1 motif and also co-localized 
with a CTCF-specific peak in all cell lines represented 
in the genome browser. Another interesting peak was 
found in the first intron of chromosome 11 open reading 
frame 54 (C11orf54) (Fig. 5A, middle panel), also known 
as the PTD012 gene. This peak contains an AR half site 
motif and FoxA1 motif (Table S6), and co-localized with 
H3K4me2, H3K4me3, H3K9ac in HepH cells. However, 
we could not verify these peaks by ChIP-PCR. 
Most notably, we found an AR binding peak 
downstream of Wig-1 (Fig 5A, bottom panel), a gene 
whose expression is known to be dependent on p53. 
Although we could not identify AR or FoxA1 response 
elements in this region, ChIP with an AR antibody 
followed by PCR with primers specific for AR validated 
that AR binds the region downstream of Wig-1. Also, 
the PCR product was observed in LNsip53 DHT-treated 
samples, but not in LNCaP control samples (Fig. 5B). 
ChIP using the FoxA1 antibody and the same primers 
failed to produce a band, and semi-quantitative PCR 
revealed that levels of the Wig-1 mRNA were lower in 
LNsip53. Semi-quantitative RT-PCR revealed that in 
LNCaP, DHT treatment led to a decrease in the levels of 
this mRNA after 24 hours, and in LNsip53, to a decrease 
at 8 hours and a further decrease by 24 hours (Fig. 5C). 
To assess the role of Wig-1 in p53-deficient cells, we 
cloned human Wig-1 into LNsip53 cells and estimated 
[3H]-thymidine uptake in those cells after treating them 
with DHT. As shown in Fig. 5D, incorporation of [3H]-
thymidine was much higher in LNsip53-Hygro cells 
than LNsip53-Wig-1 cells, as measured after treatment 
with DHT at various concentrations. We also measured 
cell proliferation in these cell lines by carrying out cell 
counts after culturing them in CSS for 11 days. As can 
be seen in Fig. 5E, Wig-1 overexpression inhibited cell 
proliferation in CSS. Thus, expression of the Wig-1 
mRNA is regulated by androgens in the absence of p53, 
and Wig-1 overexpression in LNsip53 cells inhibits their 
proliferation. This observation suggests that Wig-1 plays 
an important role in CRPC progression. 
 DISCUSSION 
The critical role of p53 in tumor development is 
well appreciated, but its role in PC is less clearly defined. 
Alterations in the p53 tumor suppressor are clearly 
associated with progressive disease, including “androgen-
independent” growth of PCs and metastases to bone [6, 8, 
23]. Loss of chromosome 17p, on which p53 is located, 
occurs with moderate frequency in advanced PC, and 
loss of one allele accompanied by point mutations in the 
remaining copy of p53 leads to functional inactivation 
(reviewed in [24]). In contrast to wild-type p53, the 
mutant protein can be stably expressed, and detection of 
high levels by immunohistochemistry is of prognostic 
significance.  Our  data  indicate  that  inhibition  of  p53 
promotes the proliferation of PC cells in the context of 
androgen deprivation. Future studies elucidating the 
details of the mechanism underlying p53’s influence on 
CRPC growth are expected to lead to the identification of 
new molecular markers and therapeutic targets. Increasing 
evidence suggests that p53 directly regulates androgen 
signaling via AR, and that this regulation can exist at 
multiple levels due to the functional complexity of both 
proteins. It was previously suggested that the presence of 
wild-type p53 at basal physiological levels is necessary for 
AR signaling [25]. In the context of this background, our 
findings support the concept of a need for balance between 
AR and p53 expression during androgen-dependent cell 
proliferation, and highlights the importance of p53 as an 
AR modulator in prostate cancer. 
Our investigation of the role of p53 in AR signaling 
in PC took advantage of LNsip53 cells, which had been 
generated in our laboratory and were described previously 
[10]. In support of previous work [8], we observed that Oncotarget 2012; 3:  183-194 191 www.impactjournals.com/oncotarget
LNsip53 can proliferate in the absence of hormones (i.e., 
in CSS). In CRPC, AR activity is thought to be maintained 
abnormally through several mechanisms, including AR 
amplification, AR mutation, an increase in AR sensitivity, 
local androgen production, and growth-factor activation 
[2, 26, 27]. 
Since eliminating p53 did not affect the binding of 
AR to specific short DNA sequences in vitro (EMSA, Fig. 
1C) but affected occupancy of the PB promoter region by 
AR and FoxA1 (Fig. 1D), we suggest that p53 elimination 
affects binding of AR to DNA at the chromatin level. 
Indeed, analysis by ChIP-seq revealed differences in the 
binding of AR to chromatin in LNCaP vs. LNsip53. In 
general the LNsip53 peaks were less numerous and of 
lower amplitude, and a lower percentage of LNsip53-
specific peaks had the expected AR motifs. 
The AR-specific peaks found in LNCaP are in a 
good agreement with those reported previously. In spite 
of the fact that we found fewer peaks than Yu et al. [21], 
probably due to our use of a monoclonal anti-AR antibody, 
75% of these matched peaks found in the earlier study. 
Also, our finding that AR is preferentially recruited to non-
promoter-regulatory elements is consistent with earlier 
findings [17, 19].
The fact that our ChIP-PCR validation was less 
successful for the LNsip53 peaks than for those in either 
the LNCaP-specific or shared groups suggests that some 
of these may either be transient or represent false positives 
– and thus may not be relevant. Further studies looking 
at additional samples, as well as analyses of peaks with 
putative AR binding sites, will be required to enumerate 
the true LNsip53-specific AR binding sites. Nevertheless, 
some validation was successful, a particularly notable 
example being our demonstration that Wig1 expression 
is reduced and that this has functional consequences. 
This  finding  supports  the  hypothesis  that AR  binding 
in the absence of p53 is physiologically relevant. Our 
further  finding  that  Wig-1  overexpression  suppressed 
the proliferation of LNsip53 cells partially explains why 
LNsip53 proliferation occurs in the absence of androgens, 
and supports the notion that p53 plays an important role in 
the progression of PC to a castration-resistant state. 
Functional FoxA1 sites were identified in the PB and 
PSA promoters, as well as other prostatic enhancers, across 
a range of species, some of these sites were immediately 
adjacent to AREs, suggesting that the organization of cis-
acting elements is well conserved, and that FoxA1 plays 
a fundamental role in prostate-specific gene expression. 
A direct interaction between FoxA1 and AR has been 
observed in these promoters, suggesting that these 
transcription factors cooperate in promoting the expression 
of androgen-regulated and prostate-specific genes [28]. 
The binding of DNA by FoxA1 has been reported to 
disrupt nucleosome formation, and thus to contribute to 
chromatin-mediated transcriptional repression [29]. We 
speculate that elimination of p53 changes the histone 
signature  around AR-specific  genes,  directly  affecting 
the priming of regulatory regions by FoxA1 binding 
and, consequently, binding of AR to the DNA. Several 
lines of evidence lead us to suggest that p53-regulated 
histone methylation involves lysine-specific demethylase 
1 (LSD1). This demethylase co-localizes with the AR in 
the normal prostate as well as in prostate cancer, interacts 
with AR in vitro and in vivo, and stimulates AR-dependent 
transcription: LSD1 inhibition abrogates androgen-
induced transcriptional activation and cell proliferation 
[30]; LSD1 forms a chromatin-associated complex with 
ligand-bound AR; LSD1 relieves repressive histone marks 
by demethylating histone H3 at lysine 9 (H3K9) (Fig. 6); 
and, complexes containing both p53 and LSD1 have been 
shown to regulate transcription in a gene-specific manner 
[31]. Thus, elimination of p53 may exert its downstream 
effects on AR-mediated transcription by interfering with 
LSD1 activity and the histone methylation profile across 
the genome. 
In conclusion, our findings suggest that reduced p53 
expression, which is frequently observed in CRPC cases, 
modifies  the  specificity  of  chromatin  binding  by AR, 
thereby leading to changes in AR-mediated signaling. 
This finding might be important for clinical prediction of 
CRPC development. Molecular markers are not routinely 
used to evaluate patients with PC because their relevance 
to important health-related outcomes has not been well 
defined. However, results of Concato et al., 2009 [32] 
suggest that p53 dysfunction is associated with increased 
risk for death from prostate cancer. Taken together our 
data suggest that understanding the p53 status is important 
for managing patients with CRPC.
METHODS
Cell lines, reagents and estimation of proliferation
The human prostate cancer cell line LNCaP was 
obtained from American Type Culture Collection, 
and the C4-2B cell line was purchased from ViroMed 
Laboratories, Inc. (Minnetonka, MN). Both cell lines were 
cultured in RPMI 1640, as previously described [10]. To 
culture cells under steroid-free conditions, RPMI 1640 
was supplemented with 10% charcoal stripped serum 
(CSS) (Hy Clone, Logan, UT, USA). The expression of 
endogenous p53 in the LNCaP, C4-2B and Rv1 cell lines 
was inhibited by infection with a recombinant lentivirus 
construct pLSL-puro expressing an siRNA hairpin against 
p53 or E6 (control), as previously described [10], resulting 
in the LNsiE6, LNsip53, C4-2BsiE6, C4-2Bsip53, 
Rv1siE6 and Rv1sip53 cell lines. For estimation of cell 
growth LNCaP, LNsiE6, LNsip53 or LNsip53Hygro 
and LNsip53-Wig1 were plated in 24-well plates at a 
concentration of 3X104, in triplicate in CCS. Cells were Oncotarget 2012; 3:  183-194 192 www.impactjournals.com/oncotarget
counted 10 days later using trypan blue to assess cell 
viability. The results for LNCaP and LNsiE6 did not differ 
and therefore only one control is shown in each Figure. 
Luciferase-reporter assay for AR activity
The luciferase reporter vector (pARE-Luc) was 
provided by Dr. Katerina Gurova (Roswell Park Cancer 
Institute, Buffalo, NY, USA) and consists of a cassette 
containing three AREs from the rat probasin promoter 
followed by an Hsp70 minimal promoter; it produces 
almost zero background expression in AR-negative 
PC cells. Cell lines possessing an integrated ARE-Luc 
reporter construct were generated by transfecting cells 
with pARE-Luc and then selecting them using G418. 
Luciferase activity was measured using a luciferase 
assay kit (Promega). The values of the luciferase assay 
were normalized with respect to the values of the protein 
concentration.
Western blot analysis
Western blot detection of proteins was performed 
as described previously [33], using mouse monoclonal 
anti-p53, anti AR, (Oncogene, Uniondale, NY, USA), anti-
Wig-1 (GeneTex, Irvine, CA, USA). 
Chromatin-immunoprecipitation and sequencing 
(ChIP-Seq)
LNCaP or LNCaPsip53 cells were cultured in 
CSS for 3 days and treated with 10 nM DHT for 1 hour. 
Samples for Solexa ChIP sequencing (ChIP-Seq) were 
prepared using ChIP IT Express Magnetic Chromatin 
Immunoprecipitation Kit (Active Motif, Carlsbad, 
CA, USA). As recommended by the manufacturer’s 
instructions, 10 µg of DNA were used for each IP probe 
and incubated with 2 µg of anti-AR mAbs overnight at 
40C. Immunoprecipitations were verified by PCR with 
primers specific for a known AR regulatory region of the 
KLK3 (PSA) promoter and enhancer described in Figure 
S3, and 200 ng of DNA were submitted for ChIP-Seq 
analysis to the DNA facility of the Iowa State University 
(ISU) office of Biotechnology.
The results of ChIP-Seq were obtained using anti-
AR or anti-FoxA1 (Santa Cruz Biotechnology, inc., 
Santa Cruze, CA, USA) antibodies as described above, 
followed by PCR with primers specific for AR binding 
regions derived after analyzing ChIP-Seq results. (For 
PCR primers sequences see Table S7) 
ChIP-Sequence data analysis
ChIP was performed with anti-AR as described 
above. Six ChIPs corresponding to three batches of 
chromatin from DHT-treated cells were pooled for a 
single  round  of  Solexa  sequencing.  Fastq  files  were 
acquired from ISU and aligned with ELAND extended. 
The fastq files were first converted to aln files using a 
simple script to rearrange the data columns. These files 
were then analyzed using cisGenome, with the following 
settings: width = 100, step size = 25, and a cutoff of 5. 
The .bar ouput files from this process were converted 
to .txt files using the program affy_bar2txt (supplied by 
cisGenome).  These  .txt  files  where  then  converted  to 
.wig files for uploading to the UCSC genome browser 
for manual viewing. The .cod files output from the same 
process as the .bar files were converted to .bed files using 
the program cod2bed (supplied by cisGenome). Partek 
GS (Partek Inc St Louis MO) was also used for peak 
prediction. Eland-aligned sequences were analyzed using 
default settings and cutoffs. These peaks were compared 
to the cisGenome peaks, and in general good agreement 
was found. However, no statistical test was possible 
due to lack of replicates. The results from Partek were 
used to generate .bed files, which were uploaded to the 
cis-regulatory element annotation system (CEAS) for 
processing, to find enriched regions and motifs [20], (Web 
Server issue):W551-4. CEAS: cis-regulatory element 
annotation system). An additional script was developed to 
extend the data from CEAS, adding additional sequence 
information as well as adjacent gene information based 
on the motif files from CEAS. This script queried the 
UCSC genome database for gene information, and used 
the alignments reported from CEAS to obtain adjacent 
sequence information. 
The Database for Annotation, Visualization and 
Integrated Discovery (DAVID) was used to identify 
functional pathway analysis [34, 35]. The short-read 
sequencing data have been deposited in the Short-Read 
Archive, under accession number GSE31294.
Electromobility shift assay (EMSA)
LNCaP and LNsip53 cells were cultured in CSS for 
3 days, and were then treated with 10 nM DHT for 1 hour. 
Nuclear proteins were isolated using NE-Per nuclear and 
cytoplasmic extraction reagents (Pierce Rockford, IL, 
USA), and EMSA was performed as described earlier [36]. 
Double-stranded AR response element oligonucleotides 
[36] (or TTRs – consensus FoxA binding sequence 
oligonucleotides) [18] (IDT, Coralville, IA), were used as 
probes to detect DNA binding. Oncotarget 2012; 3:  183-194 193 www.impactjournals.com/oncotarget
Semi-quantitative PCR
Cells were cultured in CSS medium for 3 days and 
treated with 10 nM DHT for 4, 8 or 24 hours. RNA was 
purified  using  the  RNeasy  Mini  Kit  (Qiagen).  Equal 
amounts (1 μg) of total RNA from control and treated 
cells were reverse transcribed using the iScript cDNA 
Synthesis Kit (Bio-Rad, Hercules, CA), and the cDNA (5 
μL) was amplified with primers specific for selected genes 
(for primers used in quantitative PCR see Supplemental 
Table 3). PCR was carried out in the linear range for each 
transcript, and compared GAPDH was used as a reference 
control. The PCR products were analyzed on 2% agarose 
gels. Ethidium bromide-stained gels were scanned on 
a UPV bioimaging system, and analyzed using the 
LabWorks 4.6 software (UPV, Inc, Upstate, CA, USA). 
Negative RT-PCR controls were done in the absence of 
RNA 
Wig-1 cloning
A Wig-1 was made with PCR primers based on 
the mRNA sequence of Wig-1 from Homo sapiens 
(NM_022470),  and  cloned  into  the  expression  vector 
pcDNA3.1/Hygro  (Invitrogen,  Carlsbad,  CA,  USA). 
Lipofectamine was used for transfection, according 
manufactures instructions. Empty vector was used to 
generate control cells resistant to hygromycin.
Proliferation assay
The proliferation assay was carried out as previously 
described [33]. 
Statistical analysis
Statistical analysis was performed using the 
Student’s t-test. The statistical significance was determined 
at p < 0.05. Columns and points in Figures 1, and 5 show 
mean values for four replicates in one of three separate 
experiments, all of which gave similar results; error bars 
represent the standard error of the mean (SEM). Columns 
in Figure 4 show mean values for 3 separate experiments; 
error bars represent standard deviation (SD). 
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